OBJECTIVES: Primary adenosquamous carcinoma (ASC) of the lung is rare. The current study was a retrospective two-institutional analysis of surgical therapy with respect to the clinicopathological characteristics and prognostic factors associated with ASC of the lung.
INTRODUCTION
Adenosquamous carcinoma (ASC) is a relatively rare subtype of non-small-cell lung cancer (NSCLC), which accounts for 0.4-4% of all lung cancers [1] . According to the recent WHO lung tumour classification criteria (2015 edition), ASC is defined as 'a carcinoma showing components of both adenocarcinoma and squamous cell carcinoma, with each comprising to at least 10% of the tumor' [2] . Morphologically, ASCs are mixed tumours that contain the adenomatous or squamous components. Several reports have shown that ASCs have more aggressive biological behaviour with a poorer prognosis than pure adenocarcinomas (ACs) or squamous cell carcinomas (SCCs) [1, [3] [4] [5] , suggesting that an ASC is not a simple mix of AC and SCC [6] . The biological behaviour and clinicopathological characteristics of ASC have not been thoroughly described due to the rarity of ASCs. Herein, the characteristics and predictive prognostic factors associated with ASCs are presented and discussed. tumour specimens, including the widest cross sections, are reassessed by one senior pathologist.
Preoperative examination
Routine preoperative diagnostic managements include chest and brain computed tomography (CT), bronchoscopy and abdominal ultrasound. If chest CT revealed mediastinal nodes diameter more than 1 cm, mediastinoscopy, trans-bronchial needle aspiration, endobronchial ultrasound-guided trans-bronchial needle aspiration or positron emission tomography was conducted. Serum carcinoembryonic antigen (CEA, 0-5.0 ng/ml) and carbohydrate antigen 12-5 (CA 12-5, 0-35.0 U/ml) were also included.
All patients are restaged according to the 7th edition of the tumour, node, metastasis (TNM) classification for lung cancer [7] . Postoperative chemotherapy was platinum-based.
Follow-up
Generally, patients are asked to have a routine follow-up by CT every 3 months for the first 2 years and then every 6 months at our clinic. The primary end-points of the study are disease-free survival (DFS) and overall survival (OS). DFS is defined as the interval from the date of resection to the date of proven detection of local recurrence or metastasis and OS is defined as the interval between the day of operation and the date of death by any cause, or the last follow-up date. This study was approved by the Institutional Ethics Committee.
Statistical analysis
Continuous variables were presented as mean values, and categorical variables were presented as numbers and percentages. Continuous variables were compared between groups using two-sided Student's t-tests for normally distributed data, and two-sided Wilcoxon's rank-sum tests for other data. Categorical variables were compared using contingency table analysis and χ 2 tests. Survival curves were estimated using the Kaplan-Meier method and compared using log-rank test. Univariate predictors were considered to be significant with a value of P < 0.15 and entered into a stepwise multivariable model assessed by the Cox proportional hazards model. All tests were two-sided and a value of P <0.05 was considered to indicate statistical significance. Statistical analyses were performed using SPSS software (version 19.0; IBM Corporation, Chicago, IL, USA).
RESULTS

Clinical characteristics
The clinical characteristics of the ASC patients are given in Table 1 . ASCs were more prevalent among men [n = 68 (65.4%)] than among women [n = 36 (34.6%)]. The mean age of the patients at the time of diagnosis was 60.5 years (median, 62.0 years; range, 34-82 years). The lesion is mainly peripherally located (n = 83; 79.8%). Fifty-two patients (50.0%) had an elevated preoperative CEA level and 23 (22.1%) had a high level of CA12-5. The mean level of ASC patients with CEA elevation was 26.0 ng/ml (range, 5.2-166.2 U/ml), and the mean level of ASC patients with CA 12-5 elevation was 80.1 U/ml (range, 36.5-483.4 U/ml).
Lobectomy was done in 85 (81.7%) patients, and extended resections were performed in 19 (18.3%) patients. The extended resections included sleeve resections (n = 7), bilobectomies (n = 8) and pneumonectomies (n = 4).
The T stages were as follows: T1 (n = 16), T2 (n = 76) and T3 (n = 12). The N stages were as follows: N0 (n = 48), N1 (n = 22), and N2 (n = 34). Stages I, II and IIIA were diagnosed in 39 (37.5%), 29 (27.9%) and 36 (34.6%) patients, respectively. Postoperative platinum-based chemotherapy was administrated to 87 (83.7%) patients.
Survival analysis
The mean postoperative follow-up was 37.2 months (median 35.0 months; range, 6-72 months). Sixty-two (59.6%) patients died, and 75 (72.1%) developed loco-regional recurrences (n = 29) or distant metastases (n = 46) by the last follow-up visit. The brain was the most common primary site of extrathoracic metastasis (n = 19), followed by bone (n = 11), liver (n = 6), adrenal gland (n = 3), other (n = 3) and unknown (n = 4).
The OS of all ASC stages was 57.5% at 3 years and 38.3% at 5 years. The corresponding DFS at 3 and 5 years was 38.0 and 16.9%, respectively. The 5-year OS as a function of T status was as follows: 48.5% for T1; 32.8% for T2; and 8.3% for T3 patients [T1 vs T2 (P = 0.080) and T2 vs T3, (P = 0.105) by log-rank] (Fig. 1 ). The Table 2 , which shows serum CA 12-5 level (P < 0.001), CEA in combination with CA 12-5 level (P = 0.044), T status (P = 0.026), N status (P < 0.001) and TNM status (P < 0.001) were significantly associated with OS, and the CA 12-5 level (P = 0.005), CEA in combination with CA 12-5 level (P = 0.024), N status (P < 0.001) and TNM status (P < 0.001) were significantly associated with DFS. Cox multivariate analysis of patients with resected ASCs identified the level of (Table 3) .
DISCUSSION
Due to its rarity, patients with ACS have received little attention with respect to clinical and prognostic features, and few relevant papers have been published. The present study reports a twoinstitutional surgical experience involving the ASC of the lung, and showed that ASC usually occurs in the sixth decade of life with a predominance in male and smokers, which are similar to previous reports [5, [8] [9] [10] .
ASCs are associated with aggressive behaviour. Several reports have shown that the survival outcome of ASCs is worse than that of pure ACs or pure SCCs, owing to highly aggressive pathological stages and behaviour [3, 4, 11] . Our series showed a majority of patients (54.8%) with elevated serum tumour marker level (CEA or CA 12-5 or both), a high rate of visceral pleura invasion (55.8%), a high percentage of lymph nodal metastases (53.8%) and a relatively high rate of advanced stage (IIIA, 34.6%) at the time of operation, as well as poor prognosis at each stage after the surgical intervention, which was similar to several other reports [3, 8] . Together, these findings suggest an aggressive biological behaviour of ASCs. The 5-year DFS and OS, which were not satisfactory, were in agreement with previous study [5] .
There is growing evidence that tumour markers provide prognostic information in patients with NSCLC, and it has been shown that patients with high marker levels have a worse prognosis than 
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those with normal levels [12, 13] . However, the majority of previous studies on the prognostic value of high marker levels were performed on NSCLC patients, mainly including AC and SCC, which might suffer from broad heterogeneity with respect to tumour histology. In the present study, serum CEA and CA 12-5 level, two of the most frequently tested tumour markers, were included for analysis, and half of and 22.1% of ASC cases had an elevated preoperative CEA and CA 12-5 level, respectively. Our univariate and multivariate analyses demonstrated that a high level of CA 12-5 in ASCs was significantly correlated with poor prognosis. Only a few reports available showed the importance of CA 12-5 level for primary lung carcinoma. The grade of tumour differentiation was closely correlated with biological behaviour of NSCLC. Picardo et al. [14] showed that CA 12-5 level was greater in neoplasms with a higher number of atypias, and it could be used as an effective approach for the characterization of tumours with aggressive behaviour. A study by Kimura et al. [15] showed that an increased serum CA12-5 level was observed in lung cancer patients with poor prognosis, revealing a close association between serum CA12-5 level and lung cancers. Based on these aforementioned studies, CA12-5 appeared to be associated with the histological aggressiveness of ASC that also had poorly differentiated features and it might be a potentially good prognostic indicator in ASC. As a relatively rare subtype of NSCLC, the significance of CA 12-5 elevation in Chinese patients with ASC has not been evaluated independently. The present outcomes showed that the elevated serum CA-125 was associated with poor prognosis of the ASC patients, suggesting that it can be conducive to clinical prediction of OS in ASC patients. Additional prospective trials with larger cases are required to show its potential as a biomarker of ASC. The current (7th) TNM classification of NSCLC, introduced in 2009, has a good alignment of TNM stage with prognosis, but most of the histological subtypes included for analysis were ACs and SCCs [16, 17] . This classification has not been independently validated in ASC, as a rare entity of NSCLC. In the present study, we investigated the prognosis of Stages I-IIIA ASCs of the lung in a series of Chinese patients based on the current edition of the lung cancer staging system. As shown above, there was no significant difference between patients with T1 and T2 or between those with T2 and T3; however, the OS of ASC patients differed significantly for N0, N1 and N2 status, or Stage I, II and IIIA. Cox multivariate survival analysis was performed to determine the prognostic impact of pathological stage when classified according to the current TNM system, which identified pathological TNM stage as an independent significant prognostic factor for OS. Thus, TNM stage correlated well with patient survival in the present surgical series of ASCs of the lung but not T or N status, which requires further study with larger size of sample. One of the major limitations in our series was the absence of further detailed comparisons among T1a, T1b, T2a and T2b, and Stages IA, IB, IIA and IIB, due to the insufficient statistical power with the limited sample size.
In this series, postoperative platinum-based chemotherapy was identified as a favourably independent prognostic factor for OS based on Cox multivariate analysis, which was in agreement with previous publications [3, 4, 10] . Despite the absence of prospective clinical trials, postoperative adjuvant chemotherapy treatment may be considered for all stages of ASCs due to the aggressive behaviour and poor prognosis [18] . Thus, patients with ASCs, even in an early stage, may benefit from a more aggressive and multidisciplinary approach. In addition, there are no standard adjuvant chemotherapy regimens available currently, which may require to effectively cover both the adenomatous and squamous components within ASC, and take the ratio of adenomatous or squamous components into account. Studies concerning epidermal growth factor receptor (EGFR) mutation status have been frequently conducted in ACs, while there is limited information about the prevalence of this mutation in ASC-bearing patients and the efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKIs). ASC includes adenomatous components, and in this regard, ASC patients with advanced stage are also potential candidates who can benefit a lot from EGFR-TKIs, theoretically. In recent years, an increasing number of studies demonstrated that the frequency of EGFR mutations and the clinicopathological features of the EGFR mutation in ASCs were similar to corresponding patients with ACs [19] [20] [21] , and the former could also benefit from EGFR-TKI treatment as did the latter [22, 23] . Confirmation of these findings could provide an opportunity to refine future treatment regimen studies to focus on this specific subtype, thereby increasing the survival outcomes [24] . Further insight into the genomic and molecular profile of ASCs is required to select the potential populations suitable for targeted therapy.
The major limitations of our study were the inherent selection bias of the retrospective design, and the details of the pathological characteristics of ASC, such as cell grading, the effect of structural proportion of adenomatous and squamous components within ASCs on survival were not analysed. Therefore, further study is warranted. The present study, together with other reports available, showed that ASCs of the lung had aggressive biological behaviour with a poor prognosis. Serum CA 12-5 and TNM status predict the long-term prognosis of resected primary ASC of the lung. Postoperative platinum-based chemotherapy statistically improved patients' survival. 
